NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Opinion|Videos|February 21, 2025

Strategies to Overcome CAR T Roadblocks in the Real-World Practice Setting

Author(s)Rafael Fonseca, MD, Binod Dhakal, MD, MS, Doris K. Hansen, MD

Panelists discuss how to address practical challenges in delivering chimeric antigen receptor (CAR) T cell therapy, including patient selection, bridging therapy, manufacturing delays, access barriers, and coordination of care to optimize real-world outcomes.

Episodes in this series

4 experts are featured in this series.

EP. 1 Expert Insights: Navigating the Evolving Treatment Landscape in NDMM

4 experts are featured in this series.

EP. 2 Clinical Insights: Starting with a Patient Case 1: 74yo 74-Year-Old Patient With NDMM Transplant- Ineligible NDMM

4 experts are featured in this series.

EP. 3 Evaluating Guideline-Recommended Treatment Options for Transplant-Ineligible or Transplant-Deferred NDMM

4 experts are featured in this series.

EP. 4 Diving Deep Into the CEPHEUS Trial: Subcutaneous Dara-VRd vs VRd in Transplant-Ineligible or Transplant-Deferred NDMM

4 experts are featured in this series.

EP. 5 IMROZ Data Highlights and Clinical Insights Into Quadruplet CD38-Containing Regimens in Transplant-Ineligible NDMM

4 experts are featured in this series.

EP. 6 Patient Case 2: A 65-Year-Old Patient With Standard-Risk, Transplant-Eligible NDMM

4 experts are featured in this series.

EP. 7 Selecting Among Guideline Recommended Treatment Options in Transplant-Eligible NDMM

4 experts are featured in this series.

EP. 8 PERSEUS Trial Highlights: Dara-VRd vs VRd in Transplant-Eligible NDMM

4 experts are featured in this series.

EP. 9 Clinical Perspectives: Question to Start Asking Is Who Not to Give Quadruplet CD38-Containing Regimens in Transplant-Eligible NDMM

4 experts are featured in this series.

EP. 10 Exploring Maintenance Strategies Post Autologous Transplant

4 experts are featured in this series.

EP. 11 Patient Case 4: A 58-Year-Old Woman With High-Risk MM Post HSCT With Progressive Disease—What Are Next Steps?

4 experts are featured in this series.

EP. 12 Patient Case 4: A 38-Year-Old Woman With Functional High-Risk MM With Progressive Disease at Day 60 Post ASCT—Next Treatment Approaches

4 experts are featured in this series.

EP. 13 Strategies to Overcome CAR T Roadblocks in the Real-World Practice Setting

4 experts are featured in this series.

EP. 14 CARTITUDE-4 Highlights: Cilta-Cel vs Standard of Care in R/R MM

4 experts are featured in this series.

EP. 15 CARTITUDE-4: Navigating Late CAR-T Toxicities

4 experts are featured in this series.

EP. 16 Patient Case 5: A 66-Year-Old Patient With R/R MM With Relapse Less Than 2 Years Post ASCT—Next Steps

4 experts are featured in this series.

EP. 17 KarMMa-3 Highlights: Ide-Cel vs Standard Regimens in Triple-Class– Exposed RRMM

4 experts are featured in this series.

EP. 18 KarMMa-3 Trial: Additional Insights From Ide-Cel in RRMM

4 experts are featured in this series.

EP. 19 Future Outlooks for CAR T in Early R/R Multiple Myeloma

Newsletter

Stay up to date on practice-changing data in community practice.

Related Content

On-Body Injector Technology Streamlines Subcutaneous Myeloma Therapy

ByJoseph Mikhael, MD

July 18th 2026

SC Isatuximab Approval Reflects Evolution of Patient-Centered Myeloma Care

ByJoseph Mikhael, MD

July 17th 2026

Iopofosine I 131 Shows Safety, Antitumor Activity in R/R Multiple Myeloma

ByJonah Feldman

July 16th 2026

Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm

BySumanta (Monty) Kumar Pal, MD, FASCO

July 16th 2026

Advanced Renal Cell Carcinoma: Integrating Prior Adjuvant Immunotherapy into First-Line Treatment Decisions

BySumanta (Monty) Kumar Pal, MD, FASCO

July 16th 2026

Latest CME

Wisconsin Association of Hematology and Oncology

Wisconsin Association of Hematology and Oncology

3 Sessions are Available!

Indiana Oncology Society

Indiana Oncology Society

2 Sessions are Available!

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

South Carolina Oncology Society

South Carolina Oncology Society

2 Sessions are Available!

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Aditya Bardia, MD, MPH, FASCO; Bachar Samra, MD

Breaking Down the Rationale for Targeting TROP2 in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Establishing the Rationale for ADC and ICI Combinations in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Kamel Abou Hussein, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Sara A. Hurvitz, MD, FACP; Shaina Rozell, MD, MPH

Washington State Medical Oncology Society

Washington State Medical Oncology Society

1 Session is Available!

Kansas Society of Clinical Oncology

Kansas Society of Clinical Oncology

1 Session is Available!

24th Annual International Congress on the Future of Breast Cancer® East

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Arizona Clinical Oncology Society

Arizona Clinical Oncology Society

1 Sessions is Available!

Arkansas Association of Cancer Professionals

Arkansas Association of Cancer Professionals

2 Sessions are Available!

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

9th Annual School of Nursing Oncology™

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; Cynthia X. Ma, MD, PhD

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Tiffany A. Traina, MD, FASCO; Kevin Kalinsky, MD MS, FASCO; Mark E. Robson, MD, FASCO; Rebecca Shatsky, MD

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm

On-Body Injector Technology Streamlines Subcutaneous Myeloma Therapy

Allostatic Load: The Role of Chronic Stress in Predicting Early-Onset Cancer Risk

Exploring Psilocybin-Assisted Therapy for Cancer Patients' Trauma

First Patients Dosed With TLX597-Tx in Trial for mHSPC